Sign up for our Oncology Central weekly news round-up

ZUMA-7 trial shows superiority of CAR-T cell therapy for relapsed or refractory large B-cell lymphoma

Written by Louis Gautier, Future Science Group

DUART trial

Kite, a Gilead company, recently announced top-line results from the Phase III ZUMA-7 trial investigating axicabtagene ciloleucel (Yescarta®) – a CAR-T cell therapy – in second-line relapsed or refractory large B-cell lymphoma. The trial met both primary and secondary endpoints, demonstrating superior event-free survival and objective response rates.  Standard of care for relapsed or refractory large B-cell lymphoma is a two-step process: first, immunochemotherapy is reintroduced and if the patient responds and can tolerate further treatment, they move on to high-dose chemotherapy plus stem cell transplant. The ZUMA-7 trial was initiated in 2017 and enrolled 359 patients with relapsed or refractory large B-cell lymphoma to investigate Yescarta – a CD-19 directed CAR-T cell therapy – as an alternative second-line treatment option.   Patients enrolled in the...

To view this content, please register now for access

It's completely free